Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 7, 2026, remains limited to non-exclusive internal research on peptide candidates rather than any commercial licensing commitment. Recent reporting shows the collaboration continues on track but covers unspecified compounds outside Lilly’s flagship weekly GLP-1 assets, while Lilly simultaneously advances its oral obesity pipeline. With the evaluation window closing in roughly eight weeks and no public indication of deal terms, regulatory filings, or technology transfer announcements, traders assign just 12.5% implied probability to a formal license materializing by the deadline. Key near-term catalysts include any joint-research updates or extension notices that could clarify timelines.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% โอกาส
$11,264 ปริมาณ
$11,264 ปริมาณ
Oct 7, 2026
13% โอกาส
$11,264 ปริมาณ
$11,264 ปริมาณ
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 7, 2026, remains limited to non-exclusive internal research on peptide candidates rather than any commercial licensing commitment. Recent reporting shows the collaboration continues on track but covers unspecified compounds outside Lilly’s flagship weekly GLP-1 assets, while Lilly simultaneously advances its oral obesity pipeline. With the evaluation window closing in roughly eight weeks and no public indication of deal terms, regulatory filings, or technology transfer announcements, traders assign just 12.5% implied probability to a formal license materializing by the deadline. Key near-term catalysts include any joint-research updates or extension notices that could clarify timelines.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$11,264วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 7, 2026, remains limited to non-exclusive internal research on peptide candidates rather than any commercial licensing commitment. Recent reporting shows the collaboration continues on track but covers unspecified compounds outside Lilly’s flagship weekly GLP-1 assets, while Lilly simultaneously advances its oral obesity pipeline. With the evaluation window closing in roughly eight weeks and no public indication of deal terms, regulatory filings, or technology transfer announcements, traders assign just 12.5% implied probability to a formal license materializing by the deadline. Key near-term catalysts include any joint-research updates or extension notices that could clarify timelines.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$11,264วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 7, 2026, remains limited to non-exclusive internal research on peptide candidates rather than any commercial licensing commitment. Recent reporting shows the collaboration continues on track but covers unspecified compounds outside Lilly’s flagship weekly GLP-1 assets, while Lilly simultaneously advances its oral obesity pipeline. With the evaluation window closing in roughly eight weeks and no public indication of deal terms, regulatory filings, or technology transfer announcements, traders assign just 12.5% implied probability to a formal license materializing by the deadline. Key near-term catalysts include any joint-research updates or extension notices that could clarify timelines.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย